No Data
No Data
Analysts Offer Insights on Healthcare Companies: Cullinan Management (CGEM), Ionis Pharmaceuticals (IONS) and 89bio (ETNB)
Sector Update: Health Care Stocks Mixed in Late Afternoon Trading
Health care stocks were mixed late Thursday afternoon, with the NYSE Health Care Index decreasing 0.1% and the Health Care Select Sector SPDR Fund (XLV) up 0.1%. The iShares Biotechnology ETF (IBB) wa
Biogen Also Drops Collaboration With Ionis on Angelman Syndrome Candidate
Tale Of Two Ionis-Partnered Neurology-Focused Early Stage Assets-Biogen Discontinues One, Decides Not To Exercise Licensing Option For Another
Thursday, Ionis Pharmaceuticals Inc (NASDAQ:IONS) and Biogen Inc (NASDAQ:BIIB) decided to terminate the development of BIIB105 (ION541), an investigational antisense oligonucleotide (ASO) for amyotrop
Express News | Shares of Biogen and Ionis Pharmaceuticals Are Trading Lower After the Company Discontinued Development of ALS Candidate BIIB105
Ionis to Fly Solo on Angelman Syndrome Drug -- Market Talk
1152 ET - Ionis Pharmaceuticals will advance its ION582 candidate for the genetic disorder Angelman syndrome after partner Biogen elected not to exercise its option to license and lead development of